QCG
RPRX icon

Quadrant Capital Group’s Royalty Pharma RPRX Stock Holding History

Quadrant Capital Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-677
Closed -$32.5K – 2293
2026
Q1 		$32.5K Hold
677
– – ﹤0.01% 1846
2025
Q4 		$26.2K Buy
677
+175
+35% +$6.67K ﹤0.01% 1901
2025
Q3 		$17.7K Buy
+502
New +$18.2K ﹤0.01% 1991
2025
Q2 		– Sell
-474
Closed -$14.8K – 2342
2025
Q1 		$14.8K Buy
474
+89
+23% +$2.82K ﹤0.01% 2128
2024
Q4 		$9.82K Sell
385
-775
-67% -$20.6K ﹤0.01% 2131
2024
Q3 		$32.8K Sell
1,160
-618
-35% -$17.1K ﹤0.01% 1677
2024
Q2 		$46.9K Sell
1,778
-2,210
-55% -$61.3K ﹤0.01% 1438
2024
Q1 		$121K Buy
3,988
+501
+14% +$14.8K 0.01% 902
2023
Q4 		$98K Buy
3,487
+2,606
+296% +$71.6K 0.01% 1013
2023
Q3 		$23.9K Buy
881
+652
+285% +$19.4K ﹤0.01% 1630
2023
Q2 		$7.04K Sell
229
-290
-56% -$9.82K ﹤0.01% 2117
2023
Q1 		$18.7K Buy
519
+283
+120% +$10.5K ﹤0.01% 1735
2022
Q4 		$9.33K Sell
236
-13
-5% -$543 ﹤0.01% 1982
2022
Q3 		$10K Sell
249
-118
-32% -$5.04K ﹤0.01% 1898
2022
Q2 		$15K Sell
367
-7
-2% -$287 ﹤0.01% 1446
2022
Q1 		$14K Buy
374
+122
+48% +$4.79K ﹤0.01% 1507
2021
Q4 		$10K Buy
252
+202
+404% +$7.85K ﹤0.01% 1638
2021
Q3 		$2K Sell
50
-217
-81% -$8.43K ﹤0.01% 2187
2021
Q2 		$11K Buy
267
+264
+8,800% +$11.2K ﹤0.01% 1517
2021
Q1 		$0 Hold
3
– – ﹤0.01% 2447
2020
Q4 		$0 Buy
+3
New +$127 ﹤0.01% 2365

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quadrant Capital Group's RPRX Position: Q2 2026 in Review

Quadrant Capital Group sold out of Royalty Pharma (RPRX) in Q2 2026, closing a stake of 677 shares — an estimated $32.5K sold.

Quadrant Capital Group first reported a position in RPRX in Q4 2020 and held it in 21 quarters. The position peaked at $121K in Q1 2024. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Quadrant Capital Group reported no remaining Royalty Pharma position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 677 Royalty Pharma shares in Q2 2026, an estimated $32.5K.
  • Quadrant Capital Group first reported a position in Royalty Pharma in Q4 2020 and held it in 21 quarters.
  • Quadrant Capital Group's Royalty Pharma position peaked at $121K in Q1 2024.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.